| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
115.21(B) |
| Last
Volume: |
975,365 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,137 |
144,475 |
259,873 |
619,971 |
| Total Sell Value |
$10,319,530 |
$60,539,246 |
$102,205,755 |
$209,876,745 |
| Total People Sold |
7 |
12 |
14 |
18 |
| Total Sell Transactions |
7 |
40 |
65 |
130 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-05-04 |
4 |
OE |
$86.52 |
$4,942,968 |
D/D |
43,752 |
78,855 |
|
- |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-05-04 |
4 |
AS |
$259.19 |
$607,827 |
D/D |
(2,330) |
26,838 |
|
0% |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-05-04 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
29,168 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-05-04 |
4 |
AS |
$259.21 |
$211,048 |
D/D |
(809) |
14,932 |
|
0% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-05-04 |
4 |
OE |
$86.52 |
$69,995 |
D/D |
809 |
15,741 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-05-04 |
4 |
AS |
$259.36 |
$404,957 |
D/D |
(1,553) |
35,179 |
|
0% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-05-04 |
4 |
OE |
$86.52 |
$134,366 |
D/D |
1,553 |
36,732 |
|
- |
|
| Wagner Charles F Jr |
EVP and CFO |
• – – |
2020-04-30 |
4 |
D |
$251.78 |
$137,724 |
D/D |
(547) |
16,727 |
|
- |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-04-29 |
4 |
AS |
$251.38 |
$541,769 |
D/D |
(2,125) |
26,838 |
|
5% |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-04-29 |
4 |
OE |
$90.29 |
$191,866 |
D/D |
2,125 |
28,963 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-04-28 |
4 |
AS |
$254.81 |
$290,115 |
D/D |
(1,125) |
1,875 |
|
-4% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-28 |
4 |
OE |
$57.27 |
$64,429 |
D/D |
1,125 |
3,000 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-04-27 |
4 |
AS |
$268.40 |
$542,419 |
D/D |
(2,000) |
1,875 |
|
-1% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-27 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-04-24 |
4 |
AS |
$267.23 |
$536,286 |
D/D |
(2,000) |
1,875 |
|
-0% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-24 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-04-23 |
4 |
AS |
$267.47 |
$545,052 |
D/D |
(2,000) |
1,875 |
|
5% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-23 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-04-22 |
4 |
AS |
$265.16 |
$535,753 |
D/D |
(2,000) |
1,875 |
|
2% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-22 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-04-21 |
4 |
AS |
$263.20 |
$533,523 |
D/D |
(2,000) |
1,875 |
|
6% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-21 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-04-20 |
4 |
AS |
$269.97 |
$546,310 |
D/D |
(2,000) |
1,875 |
|
-1% |
|
| Lee Yuchun |
Director |
– • – |
2020-04-20 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-04-13 |
4 |
AS |
$244.09 |
$213,650 |
D/D |
(859) |
14,932 |
|
10% |
|
3277 Records found
|
|
Page 24 of 132 |
|
|
1.92 (0.44%) 
